Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues

Hepatology

Volumn 51, Issue 1, 2010, Pages 73-80

  Van Bömmel, Florian ^a   De Man, Robert A ^b   Wedemeyer, Heiner ^c   Deterding, Katja ^c   Petersen, Jörg ^d   Buggisch, Peter ^d   Erhardt, Andreas ^e   Hüppe, Dietrich ^f   Stein, Kerstin ^g   Trojan, Jörg ^h   Sarrazin, Christoph ^h   Böcher, Wulf O ⁱ   Spengler, Ulrich ^j   Wasmuth, Hermann E ^k   Reinders, Jurrien G P ^b   Möller, Bernd ^l   Rhode, Peter ^m   Feucht, Heinz Hubert ^f   Wiedenmann, Bertram ^a   Berg, Thomas ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d UNIVERSITY OF HAMBURG   (Germany)

^e UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^f Gastroenterologische Schwerpunktpraxis Herne ^*  (Germany)

^g UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^h UNIVERSITY HOSPITAL FRANKFURT   (Germany)

ⁱ JOHANNES GUTENBERG UNIVERSITY   (Germany)

^j UNIVERSITY OF BONN   (Germany)

^k UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^l Hepatologische Schwerpunktpraxis   (Germany)

^m St Marien Hospital Hamm   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; TENOFOVIR DISOPROXIL; VIRUS DNA;

ADD ON THERAPY; ADOLESCENT; ADULT; AGED; ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; GENOTYPE; HEPATITIS B; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION; VIROLOGY;

ADENINE; ADOLESCENT; ADULT; COHORT STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 73449121925     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.23246     Document Type: Article

References (24)

1. Lampertico P, Viganò M, Manenti E, Iavarone M, Lunghi G, Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. HEPATOLOGY 2005;42:1414-1419.
2. De Clercq E, Holy A. Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nat Rev Drug Discov 2005;4:928-940.
3. van Bömmel F, Wünsche T, Schürmann D, Berg T. Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication. HEPATOLOGY 2002;36:507-508.
4. Núñez M, Pérez-Olmeda M, Diaz B, Rios P, Gonzalez-Lahoz J, Soriano V. Activity of tenofovir on hepatitis B virus replication in HIV co-infected patients failing or partially responding to lamivudine. AIDS 2002;16:23524.
5. Benhamou Y, Tubiana R, Thibault V. Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus. N Engl J Med 2003;348:1778.
6. van Bömmel F, Wünsche T, Mauss S, Reinke P, Bergk A, Schürmann D, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. HEPATOLOGY 2004;40:1421-1425.
7. Peters MG, Andersen J, Lynch P, Liu T, Alston-Smith B, Brosgart CL, et al. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. HEPATOLOGY 2006;44:1110-1116.
8. van der Eijk AA, Hansen BE, Niesters HG, Janssen HL, van de Ende M, Schalm SW, et al. Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants. J Viral Hepat 2005;12:364-372.
9. van Bömmel F, Zöllner B, Sarrazin C, Spengler U, Hüppe D, Möller B, et al. Tenofovir rescue therapy for patients with lamivudine-resistant hepatitis B virus (HBV) infection showing persistent high level replication during adefovir therapy. HEPATOLOGY 2006;44:318-325.
10. Schmutz G, Nelson M, Lutz T, Sheldon J, Bruno R, van Bömmel F, et al. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. AIDS 2006;20:1951-1954.
11. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359:2442-2455.
12. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004;292:191-201.
13. Qi X, Xiong S, Yang H, Miller M, Delaney WE III. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther 2007;12:355-362.
14. Delaney WE 4th, Ray AS, Yang H, Qi X, Xiong S, Zhu Y, et al. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother 2006;50:2471-2477.
15. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. HEPATOLOGY 1998;27:1670-1677.
16. Stuyver LJ, Locarnini SA, Lok A, Richman DD, Carman WF, Dienstag JL, et al. Nomenclature for antiviral-resistant human hepatitis B virus DNA in two international reference plasma preparations. HEPATOLOGY 2001;33:751-757.
17. Norder H, Hammas B, Löfdahl S, Courouce' AM, Magnius LO. Comparison of the amino acid sequences of nine different serotypes of hepatitis B surface antigen and genomic classification of the corresponding hepatitis B virus strains. J Gen Virol 1992;73:1201-1208.
18. Lada O, Benhamou Y, Cahour A, Katlama C, Poynard T, Thibault V. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. Antivir Ther 2004;9:353-363.
19. Yang H, Qi X, Sobogai A, Miller M, Xiong S, Delaney WE IV. Crossresistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther 2005;10:625-633.
20. Berg T, Möller B, Trinh H, Chan S, Marcellin P, Suarez E, et al. Tenofovir disoproxil fumarate (TDF) versus emtricitabine plus TDF for treatment of chronic hepatitis B (CHB) in subjects with persistent viral replication receiving adefovir dipivoxil (ADV) [Abstract]. J Hepatol 2008;48:34A.
21. van Bömmel F, Trojan J, Feucht HH, Möller B, Hüppe D, Wiedenmann B, et al. Tenofovir shows limited efficacy in treatment of HBV infections resistant against adefovir [Abstract]. HEPATOLOGY 2007;46:664A.
22. Snow-Lampart A, Sorbel J, Chappell B, Curtis M, Zuh Y, Borroto-Esoda K. Lack of tenofovir DF (TDF) resistance mutations in treatment-naïve and treatment-experienced subjects with chronic HBV infection following 48 weeks of TDF mono-therapy. EASL-AASLD-APASL-IASL Conference Hepatitis B&C virus resistance to antiviral therapies. Paris, France; February 14-16, 2008. Abstract.
23. Cornberg M, Protzer U, Dollinger MM, Petersen J, Wedemeyer H, Berg T. Prophylaxis, diagnosis and therapy of hepatitis B virus (HBV) infection: the German guidelines for the management of HBV infection. Z Gastroenterol 2007;45:1281-1328.
24. Tan J, Degertekin B, Wong SN, Husain M, Oberhelman K, Lok AS. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J Hepatol 2008;48:391-398.